1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,980 | 0,985 | 11:38 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 04:02 | Abbisko's Lavengratinib Shows Early Height-Growth Benefit In Phase II Achondroplasia Study | 1 | RTTNews | ||
| 03:00 | Abbisko Therapeutics Announces Positive Preliminary Phase 2 Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia | 65 | PR Newswire | SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- 21 September 2026 (Beijing time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK)... ► Artikel lesen | |
| 02:00 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES POSITIVE PRELIMINARY PHASE II RESULTS WITH LAVENGRATINIB (ABSK061) FOR THE ... | 1 | HKEx | ||
| Do | ABBISKO-B (02256): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON SEPTEMBER 17, 2026 | - | HKEx | ||
| Mi | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 08.09. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 01.09. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 31.08. | ABBISKO-B Completes First Patient Dosing in Phase I Trial of Pan-KRAS Inhibitor ABSK211 | 1 | AASTOCKS | ||
| 31.08. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING IN PHASE I CLINICAL TRIAL OF NOVEL PAN-KRAS INHIBITOR ... | 1 | HKEx | ||
| 28.08. | ABBISKO-B (02256): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 28.08. | ABBISKO-B (02256): PROXY FORM FOR EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 28.08. | ABBISKO-B (02256): PROPOSED CHANGE OF COMPANY NAME AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 25.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 24.08. | ABBISKO-B (02256): PROPOSED CHANGE OF COMPANY NAME | 1 | HKEx | ||
| 24.08. | ABBISKO-B (02256): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 19.08. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES IND CLEARANCE FROM THE NMPA FOR ORAL SMALL MOLECULE PAN-KRAS INHIBITOR ABSK211 | 1 | HKEx | ||
| 03.08. | ABBISKO-B (02256): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES IND CLEARANCE FROM THE FDA FOR ORAL SMALL MOLECULE PAN-KRAS INHIBITOR ABSK211 | 1 | HKEx | ||
| 08.07. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 02.07. | Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance | 6 | Benzinga.com |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| ELECTRA THERAPEUTICS | 13,500 | 0,00 % | HBM Healthcare Investments AG: HBM Healthcare Investments gibt Börsengang der Portfoliogesellschaft Electra Therapeutics bekannt | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments gibt Börsengang der Portfoliogesellschaft Electra Therapeutics bekannt
21.09.2026 /... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,850 | 0,00 % | Candel Therapeutics auf der H.C. Wainwright Konferenz: Fokus auf Prostatakrebs-Therapie | ||
| COGENT BIOSCIENCES | 31,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,80 | 0,00 % | Kymera Therapeutics auf Morgan Stanley Konferenz: Offensive bei oralen Degradern | ||
| RECURSION PHARMACEUTICALS | 3,830 | 0,00 % | Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,055 (+5,91 %) liegt der Kurs bei 0,985 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.